Characteristic immunologic profile of large atypical cells in lymphomatoid papulosis. Possible implications for histogenesis and relationship to other diseases

Kadin, Marshall E.

doi:10.1001/archderm.122.12.1388

Cited by 13 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings support the previously published impression that granulomas and a monomorphous lymphoid infiltrate are uncommon in LyP. [3][4][5][6][7]10,11,23 None of the patients in our study had development of an associated lymphoma. Although 3 previous series of case reports failed to detect associated hematologic malignancies (mean follow-up: 12.2 years, 5 4 years, 7 and 4.6 years 8 ), Nijsten et al 4 described 3 cases in a cohort of 35 (9%) with associated non-Hodgkin lymphoma (median follow-up: 9 years).…”

Section: Discussionsupporting

confidence: 92%

Clinical, histopathologic, and immunophenotypic features of lymphomatoid papulosis with CD8 predominance in 14 pediatric patients

Souza

Camilleri

Wada

et al. 2009

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

Clinical, histopathologic, and immunophenotypic features of lymphomatoid papulosis with CD8 predominance in 14 pediatric patients

Souza

Camilleri

Wada

et al. 2009

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…CD30 (TNFRSF 8) is a transmembrane protein, a member of the tumor necrosis factor (TNF) receptor superfamily. It was originally described as a marker for Reed-Sternberg cells ("Ki-1 antigen") in Hodgkin's disease (12,18,20). CD30 is expressed on CD4 ϩ and CD8 ϩ T cells that secrete Th-2 type cytokines (8, 17).…”

mentioning

confidence: 99%

“…It was originally described as a marker for Reed-Sternberg cells ("Ki-1 antigen") in Hodgkin's disease (12,18,20). CD30 is expressed on CD4 ϩ and CD8 ϩ T cells that secrete Th-2 type cytokines (8,17).…”

mentioning

confidence: 99%

Development and Validation of a Fluorescent Microsphere Immunoassay for Soluble CD30 Testing

Pavlov¹,

Martins²,

Delgado

2009

Clin Vaccine Immunol

View full text Add to dashboard Cite

Testing for soluble CD30 (sCD30), an indicator of Th2 immune response, is a useful prognostic marker in solid organ transplantation, lymphoproliferative disorders, autoimmunity, and various parasitic diseases. In this study we report the development and validation of a fluorescent microsphere immunoassay for the detection of sCD30 in serum, plasma, and culture supernatants. The dynamic range of this assay is 1 to 400 ng/ml, and the rate of recovery of various concentrations of recombinant sCD30 ranges from 97 to 116% (average recovery, 105%). The test showed a high degree of precision in both intra-assay and interassay studies (coefficients of variation, as high as 7% and 8%, respectively), with a sensitivity of 1 ng/ml. The normal reference range calculated for a cohort of 151 healthy individuals was 1 to 29 ng/ml. The clinical usefulness of the sCD30 fluorescent microsphere immunoassay was demonstrated by showing that levels of sCD30 have a positive correlation with specimens containing high titers of anti-double-stranded DNA antibodies and high titers of immunoglobulin G against Leishmania species. Given the multiplexing potential of the sCD30 fluorescent microsphere immunoassay reported in this study, it is expected that testing of sCD30 concentrations along with those of other cytokines will become an important diagnostic tool for selected immunological and inflammatory diseases where Th2-type cytokine responses have been reported. CD30 (TNFRSF 8) is a transmembrane protein, a member of the tumor necrosis factor (TNF) receptor superfamily. It was originally described as a marker for Reed-Sternberg cells ("Ki-1 antigen") in Hodgkin's disease (12,18,20). CD30 is expressed on CD4 ϩ and CD8 ϩ T cells that secrete Th-2 type cytokines (8, 17). Signaling through CD30 plays important roles in T-and B-cell growth, differentiation, and function. The soluble form of CD30 (sCD30) is produced after proteolytic cleavage of the membrane-bound CD30 ectodomain by the TNF-␣-converting enzyme (9).Numerous studies have reported that circulating levels of sCD30 may represent a biomarker for outcomes in solid-organ transplantation (16,21). In addition, other studies have reported that levels of sCD30 have important prognostic value for various lymphoproliferative disorders (4,15,22), systemic lupus erythematosus (SLE) (5, 7), and leishmaniasis (1, 2). The current method for quantitation of sCD30 is the enzyme-linked immunosorbent assay (ELISA), which has good sensitivity and specificity. However sCD30 production differs greatly between patients, and the dynamic range of ELISAs requires that many samples be diluted and retested. Moreover, ELISA measures only 1 analyte per well, which precludes the testing of multiple analytes in the same test. In this study, we report the development and validation of a fluorescent microsphere immunoassay suitable for multiplexed determination of sCD30 levels, along with those of other cytokines, in serum and plasma specimens and in tissue culture supernatants. We present data showing the positiv...

show abstract

“…These atypical cells normally express a T‐cell phenotype with variable loss of pan‐T antigens (CD2, CD3, CD5, CD7). Most cases have a CD4+ T‐cell phenotype, whereas only some cases express a CD8+ T‐cell phenotype 3 . Expression of CD15 is rare.…”

mentioning

confidence: 99%

Lymphomatoid papulosis with a natural killer-cell phenotype.

Bekkenk¹,

Kluin

Jansen

et al. 2001

Br J Dermatol

View full text Add to dashboard Cite

Lymphomatoid papulosis (LyP) is defined as a recurrent self-healing papulonodular eruption with the histological features of a (CD30+) cutaneous T-cell lymphoma. The atypical cells usually have a CD3+/-, CD4+/-, CD8-, CD30+, CD56- T-cell phenotype. We report an unusual case of LyP, in which the atypical cells expressed a CD3-, CD4-, CD8-, CD30+, CD56+ phenotype. Detailed phenotypic and genotypic analysis confirmed that these cells had a natural killer (NK)-cell phenotype. Lymphomas with an NK-cell phenotype usually have a poor prognosis. However, the waxing and waning of papular lesions for more than 20 years and the excellent response to low-dose oral methotrexate in this patient suggest similar clinical behaviour to LyP cases with a T-cell phenotype.

show abstract

Characteristic immunologic profile of large atypical cells in lymphomatoid papulosis. Possible implications for histogenesis and relationship to other diseases

Cited by 13 publications

References 0 publications

Clinical, histopathologic, and immunophenotypic features of lymphomatoid papulosis with CD8 predominance in 14 pediatric patients

Clinical, histopathologic, and immunophenotypic features of lymphomatoid papulosis with CD8 predominance in 14 pediatric patients

Development and Validation of a Fluorescent Microsphere Immunoassay for Soluble CD30 Testing

Lymphomatoid papulosis with a natural killer-cell phenotype.

Contact Info

Product

Resources

About